These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Early phase II trial of bestrabucil in hematological malignancies].
    Author: Nagura E, Ohno R, Yamada K, Akao Y, Naito K, Nishikawa M, Tanaka H, Shirakawa S, Ono Y, Ezaki K.
    Journal: Gan To Kagaku Ryoho; 1986 Jun; 13(6):2216-22. PubMed ID: 3459398.
    Abstract:
    Thirty-three patients with various hematological malignancies were treated with Bestrabucil, the benzoate of an estradiol-chlorambucil conjugate, at doses of 50-300 mg daily p.o., consecutively. Nineteen patients had previously received chemotherapy. Of 29 evaluable patients, there were one CR and three PRs among 6 patients with chronic lymphocytic leukemia, two CRs and one PR among 4 patients with malignant lymphoma, two PRs among 3 patients with adult T-cell leukemia, one PR among 4 patients with macroglobulinemia, one PR for one patient with essential thrombocythemia, and one PR for a patient with chronic myelocytic leukemia. Main side effects included G1 symptoms (14%), estradiol-related symptoms (24%) and myelosuppression (32%).
    [Abstract] [Full Text] [Related] [New Search]